uk broker tips increased relenza revenue, page-2

According to this article earnings by GSK of 750million pounds in 2009 represents only about 60 million doses and sales of 1billion pounds in 2010 only represents GSK sales of around 80 million doses.

The numbers still don't stack up as to why GSK have announced they are increasing manufacturing to 190 million doses per annum whilst the analysts predict something else.

I still think the analysts have got it wrong and that an explosion of flu cases in the very soon to hit northern winter will see demand for Relenza well in XS of 100 million doses per annum and closer to 150 million doses per annum.

With 6 billion people on the planet and at least 1 billion who can afford the drug, selling only 60-80 million doses each year dosn't add up!